---
title: "688222.SH (688222.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688222.SH/news.md"
symbol: "688222.SH"
name: "688222.SH"
parent: "https://longbridge.com/en/quote/688222.SH.md"
datetime: "2026-05-21T01:56:51.196Z"
locales:
  - [en](https://longbridge.com/en/quote/688222.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688222.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688222.SH/news.md)
---

# 688222.SH (688222.SH) — Related News

### [STAR Market Evening News | Rendu Biotechnology's controlling shareholder plans to change control; HitGen's shareholders intend to reduce their holdings by no more than 3.51%](https://longbridge.com/en/news/285556813.md)
*2026-05-07T12:57:19.000Z*
> The main content of the Sci-Tech Innovation Board Evening News includes: 1) The large medical model developed in Shangha

### [HitGen: Shareholder Huabo Medical Equipment plans to reduce its holdings by 1%, Shenzhen JunTian plans to reduce its holdings by 2.51%](https://longbridge.com/en/news/285518619.md)
*2026-05-07T09:15:29.000Z*
> HitGen announced that its shareholder Huabo Medical plans to reduce its holdings by no more than 4 million shares, accou

### [07:00 ETESG | HitGen Releases 2025 Sustainability Report](https://longbridge.com/en/news/284553303.md)
*2026-04-29T11:02:18.000Z*
> HitGen Inc. (SSE:released its 2025 Sustainability Report on April 29, 2026. The report outlines the company's ESG philos

### [HitGen's revenue and net profit are expected to grow significantly in 2025, with the commercial transformation of its new technology business segment gradually becoming apparent](https://longbridge.com/en/news/284410961.md)
*2026-04-28T14:44:32.000Z*
> On the evening of April 28th, HitGen (688222) announced its 2025 annual report and the first quarter report for 2026, in

### [HitGen: Net profit in the first quarter was 41.5002 million yuan, a year-on-year increase of 46.72%](https://longbridge.com/en/news/284363879.md)
*2026-04-28T10:35:00.000Z*
> HitGen announced that its revenue for the first quarter of 2026 was 161 million yuan, a year-on-year increase of 50.40%;

### [The medical services sector opened weaker](https://longbridge.com/en/news/281592181.md)
*2026-04-03T01:38:06.000Z*
> The medical services sector opened weaker, with ChemPartner, R&G Pharma, and HITECK falling over 5%, followed by INKON L

### [](https://longbridge.com/en/news/280715789.md)
*2026-03-27T02:13:17.000Z*
> The A-share CRO concept sector continued to strengthen during the trading session, with INNOSTAR rising over 11%, Menovo

### [Xian Derivatives completed a Series A financing of 150 million yuan to accelerate the clinical advancement of its core pipeline and the optimization and upgrading of its technology platform](https://longbridge.com/en/news/279876904.md)
*2026-03-20T02:40:19.000Z*
> HitGen recently completed a Series A financing of 150 million yuan, led by DaoYuan Capital, with QiShen Venture Capital